EXAS Stock Set to Benefit From Favorable Study Data Backing MCED Test

Exact Sciences Corporation (EXAS) has unveiled data highlighting significant advancements in the development of a multi-cancer early detection (MCED) test. The results of the DETECT-A (Detecting cancers Early Through Elective mutation-based blood Collection and Testing) study, which evaluated a new multi-biomarker class approach, showed improved sensitivity for early-stage and overall cancer detection.The findings from the study were presented at the AACR (American Association of Cancer Research) Special Co ...